Compounding Unlikely To Solve GLP-1 Affordable Access Issues

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

Mortar
• Source: Shutterstock

According to a new report from the Institute for Clinical and Economic Review (ICER) on the affordability of obesity drugs, compounding is not likely to be a solution to concerns about access and affordability for GLP-1 receptor agonists, especially in obesity.

Key Takeaways
  • A white paper by ICER laid out ways to address the issue of affordability and access to GLP-1 receptor agonists, but said compounding is not likely to provide a long-term solution.

A 9 April white paper by ICER explored ways to control the cost of GLP-1 drugs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from Market Access